Alerta

STABLE LIPID OR LIPIDOID NANOPARTICLE SUSPENSIONS

Resumen de: US20260325445A1

0000 Provided are stabilized lipid nanoparticle (LNP)/lipidoid nanoparticle (LiNP) formulations and LNP/LiNP suspensions, uses thereof and uses in method of treatment based on the findings that the addition of the surfactant to the formulations or suspensions avoids aggregation, allowing a surprisingly long shelf life and extended stability to shaking. Said reduction of aggregation according to the invention results in a reduction of side effects of the formulations and suspension of the invention, specifically a reduction of side effects caused by vaccines formulations and anticancer formulations comprising LNPs and/or LiNPs

STIMULI-RESPONSIVE STING-ACTIVATING POLYMER COMPOSITIONS AND METHODS OF USE

Resumen de: WO2025129124A1

Compositions and methods for treating a cancer or an infectious disease by delivering a compound comprising a polymeric backbone and a STING agonist covalently linked by a stimulus responsive linker are provided.

METHODS OF DELIVERING THERAPEUTICS USING LIPID NANOPARTICLES

Resumen de: WO2025132122A1

Disclosed herein are methods for delivering therapeutic agents using lipid nanoparticles (LNPs) containing at least one compound of Formula (I) or a pharmaceutically acceptable salt, tautomer, hydrate, solvate, stereoisomer, or isotope thereof, wherein R1, R2, R3, m, and n are as defined herein. Also disclosed are methods for treating mucosal disorders with LNPs including the compound of Formula (I).

COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY OF THERAPEUTIC COMPOUNDS

Resumen de: WO2025129128A1

The present disclosure provides compositions and methods for non-viral delivery of therapeutics, and methods of preparing said compositions.

TOLERIZING IMMUNOMODULATORY COMBINATION

Resumen de: MX2026007279A

An immunomodulatory combination that includes a first lipid conjugate, a second lipid conjugate, and one or more nucleic acids. The first lipid conjugate includes a corticosteroid covalently linked to a first lipophilic moiety by a first cleavable linkage or through a first cleavable linker. The second lipid conjugate includes an mTOR/mTORC inhibitor covalently linked to a second lipophilic moiety by a second cleavable linkage or through a second cleavable linker. The one or more nucleic acids encode one or more epitopes targeted by autoreactive T cells, wherein the one or more epitopes comprise one or more class II epitopes. The first lipid conjugate, the second lipid conjugate, and the one or more nucleic acids are co-formulated together in a delivery vehicle, or are formulated in two or three separate delivery vehicles. The immunomodulatory combination may be used for treating autoimmune diseases or conditions involving autoreactive T cells, which includes both CD4+ T cells and CD8+ T cells.

IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF

Resumen de: WO2025128902A1

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.

SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERY

Resumen de: WO2025123134A1

The present application relates to ionizable lipids that include ester functional groups. The present application further relates to compositions and uses thereof for the delivery of agents such as nucleic acids and drugs.

GLUCOSE-DEPENDENT DROPLETS AND SUPRAMOLECULAR PEPTIDE DEPOTS FOR GLUCOSE-RESPONSIVE GLUCAGON DELIVERY

Resumen de: WO2025128687A1

Described herein are peptide amphiphiles (PAs) for inclusion in droplets and hydrogels.

CATIONIC LIPID AND USE THEREOF

Resumen de: EP4825838A1

The present disclosure relates to a cationic lipid and use thereof. Specifically provided is a compound represented by formula I or a salt thereof, wherein R¹ to R⁴, H¹, H², and L¹ are as defined in the present disclosure. The cationic lipid is used for delivering polynucleotides or nucleic acids and protecting the polynucleotides or nucleic acids from being degraded and removed in serum, and has excellent delivery efficiency.

DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES

Resumen de: WO2025128916A1

Systems for analyzing biological components are provided. The systems may include a fluidic device and an energy source in communication with the fluidic device. The energy source may supply energy to the fluidic device to form a polymer matrix on or adjacent to a biological component within the fluidic device. Methods of using the systems to analyze biological components are also provided.

COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTION

Resumen de: WO2025129174A1

Tuberculosis (TB) remains a leading cause of death from infectious disease worldwide, in part due to the limited efficacy of currently available vaccine. Disclosed herein are compositions and methods for providing immunogenic protection against TB.

HYDROGEL COMPOSITIONS

Resumen de: WO2025125384A1

The present invention relates to compositions comprising metal-organic framework (MOF) nanoparticle or nanoparticles, methods of preparing said compositions, methods of treatment using said compositions, and uses of said compositions.

IMIDAZOLE LIPID AND USE THEREOF

Resumen de: EP4825843A1

0001 The present disclosure relates to an imidazole lipid and a use thereof. Specifically, provided are a compound represented by formula I or a salt thereof, and a lipid particle or a pharmaceutical composition containing the compound. The compound can be used as a delivery system, and is used for preparing drugs for preventing and/or treating cancers, infectious diseases, autoimmune diseases, neurodegenerative diseases, inflammation, etc. The definition of each group in formula (I) is as described in the description.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: AU2024398058A1

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

CATIONIC LIPID COMPOUNDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025128696A1

Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3a, R3b, R3c, R3d, L1, L2, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES

Resumen de: EP4825362A1

0001 Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are exogenously loaded with bioactive cargo or other cargo of interest, such as for therapeutic, industrial, diagnostic, and cosmetic uses. The MEVs have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as diagnostics, and other such uses.

MOLECULAR CAPSULE COMPRISING QUERCETIN COATED WITH POLYPEPTIDES AND PREPARATION METHOD THEREFOR

Resumen de: EP4825376A1

The present disclosure belongs to the technical field of molecules, and particularly relates to a polypeptide-encapsulated quercetin molecular capsule and a preparation method therefor. The method includes steps of: (1) mixing amino acid A, quercetin, and water in a ratio, followed by ultrasonic enzymolysis to prepare a precursor; (2) mixing the precursor with amino acid B in a ratio to prepare a molecular capsule precursor; and (3) adding the molecular capsule precursor into a crystallizer for recrystallization of an outer structure, and performing filtering and high-pressure drying to prepare the polypeptide-encapsulated quercetin molecular capsule. The present disclosure can effectively improve the bioavailability of the quercetin in the constructed molecular capsule by optimizing the powder properties of the drug crystal, and implement controllable sustained release through a specific particle size, thus better controlling the release rate and release amount of the quercetin.

COMPOSITION AND COMPOUND FOR DELIVERING THERAPEUTIC AGENT

Resumen de: EP4825375A1

A lipid nanoparticle composition for delivering a therapeutic agent, comprising a compound of formula I or compounds of formula I and formula II, or a salt thereof.

INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES

Resumen de: WO2025128913A1

Composition and methods for preventing or reducing inflammation resulting from nanoparticle administration to a subject are provided. In one embodiment a method of delivering an agent to a target organ of a subject, comprises administering to the subject a galectin inhibitor and a nanoparticle comprising the agent, wherein inflammation resulting from administration of the nanoparticle is reduced or prevented.

STABILIZATION OF LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2025128958A1

Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a citrate drug product matrix, EDTA drug product matrix, methionine drug product matrix, and/or a tryptophan drug product matrix. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.

DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF

Resumen de: EP4825839A1

0001 The present application relates to a cationic lipid containing a disulfide bond of Formula (1), wherein, -S-S- is a disulfide bond; L<1> and L<2> are each independently a degradable divalent linking group, X<1> and X<2> are each independently an acyclic divalent linking group containing a tertiary amine group; G<1> and G<2> are each independently a linking bond or a trivalent branching group; when G<1> is a linking bond, k1 is 1; when G<1> is a trivalent branching group, k1 is 2; when G<2> is a linking bond, k1 is 1; when G<2> is a trivalent branching group, k2 is 2; R<1> and R<2> are each independently a substituted or unsubstituted C<5-30> hydrocarbon group or C<5-30> hydrocarbon derivative residue. The lipid composition prepared with the cationic lipid of the present application, under the premise of good ability to complex with nucleic acid drugs, stability in the systemic circulation, and low toxicity, can more effectively exert the therapeutic effect of the LNP-nucleic acid pharmaceutical composition formulation, thereby improving immunological or therapeutic outcomes.

circWHSC1在制备用于治疗和/或预防体内血栓形成相关疾病的产品中的应用

Resumen de: CN122937084A

本发明公开了circWHSC1在制备用于治疗和/或预防体内血栓形成相关疾病的产品中的应用。circWHSC1为mmu_circ_0001336，经LNP包裹后静脉注射给药。经小鼠颈动脉血栓模型实验证实，circWHSC1@LNP可显著减小血栓长度、重量和面积；提前给药可延缓血栓造模后血流灌注下降；并可减少血栓纤维化程度、纤维蛋白数量、宽度和面积，抑制血小板黏附聚集。本发明可将circWHSC1作为药物靶点，用于制备治疗急性心肌梗死、脑梗死、下肢动脉血栓栓塞、急性下肢动脉闭塞、深静脉血栓、肺血栓栓塞症、门静脉血栓、肾静脉血栓等血栓形成相关疾病的药物。

一种基于海洋生物来源DHA的可电离脂质及其制备方法与应用

Resumen de: CN122940679A

本发明属于生物医药技术领域，涉及一种基于海洋生物来源DHA的可电离脂质及其制备方法与应用。其化学结构式如式I所示；。本发明提供的可电离脂质兼具良好的pH响应性，抗炎特性及生物相容性，组装形成的脂质纳米颗粒能高效包裹核酸类药物，促进药物的细胞内吞及内体逃逸。

一种具有AIE特性的有机小分子及其制备方法和应用

Resumen de: CN122940768A

本发明公开了一种具有AIE特性的有机小分子及其制备方法和应用，属于功能材料和药物制剂技术领域，该具有AIE特性的有机小分子将硒二唑并3,4‑f苯并c1,2,5噻二唑与给电子基团进行共轭连接，具有分子内电荷转移特性的D‑A‑D型结构，进一步采用两亲性材料包裹该具有AIE特性的有机小分子后得到的纳米粒子可作为肿瘤治疗制剂和/或成像制剂应用，其具有近红外二区的吸收能力、AIE特性、较好的荧光量子产率和较高的光热转换效率，在体外实验中，表现出良好的生物相容性、较好的光毒性，具有良好的应用前景。

一种用于抗肿瘤的复合物及其制备方法和应用

Nº publicación: CN122937094A 20/10/2026

Solicitante:

中国医学科学院生物医学工程研究所

Resumen de: CN122937094A

本发明公开了一种用于抗肿瘤的复合物及其制备方法和应用，涉及生物医药技术领域。该制备方法包括以下步骤：将衰老肿瘤细胞外泌体与SR‑717进行混合反应，使所述SR‑717负载于所述衰老肿瘤细胞外泌体中，制备得到所述用于抗肿瘤的复合物。本发明通过将衰老肿瘤细胞外泌体与STING激动剂SR‑717相结合，在同一体系中实现了免疫调控功能与免疫激活信号的协同增强，从而有利于实现更为有效和可控的抗肿瘤免疫治疗。同时，通过外泌体对SR‑717进行包载，有助于减少游离药物在非靶组织中的扩散，降低非特异性免疫激活和系统性炎症反应的风险。